'Se­ri­ous liv­er in­jury' cas­es lead FDA to call for mon­i­tor­ing of Ocali­va pa­tients

The FDA said it con­tin­ues to mon­i­tor the safe­ty of In­ter­cept Phar­ma­ceu­ti­cals and Al­fasig­ma’s rare liv­er dis­ease drug Ocali­va af­ter see­ing ev­i­dence of “se­ri­ous liv­er …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER